Abstract:
Purpose: The Pediatric Oncology in Developing Countries (PODC) committee of the
International Society of Pediatric Oncology (SIOP) published a pediatric acute mye-
loid leukemia (AML)-specific adapted treatment guideline for low- and middle-income
countries. We evaluated the outcomes of children with AML at a large Kenyan aca-
demic hospital before (period 1) and after (period 2) implementing this guideline.
Patients and Methods: Records of children (≤17 years) newly diagnosed with AML
between 2010 and 2021 were retrospectively studied. In period 1, induction therapy
comprised two courses with doxorubicin and cytarabine, and consolidation com-
prised two courses with etoposide and cytarabine. In period 2, a prephase with intra-
venous low-dose etoposide was administered prior to induction therapy, induction
course I was intensified, and consolidation was adapted to two high-dose cytarabine
courses. Probabilities of event-free survival (pEFS) and overall survival (pOS) were
estimated using the Kaplan–Meier method.
Results: One-hundred twenty-two children with AML were included – 83 in period 1
and 39 in period 2. Overall, 95 patients received chemotherapy. The abandonment
rate was 19% (16/83) in period 1 and 3% (1/39) in period 2. The early death,
treatment-related mortality, complete remission, and relapse rates in periods 1 and
2 were 46% (29/63) versus 44% (14/32), 36% (12/33) versus 47% (8/17), 33%
(21/63) versus 38% (12/32), and 57% (12/21) versus 17% (2/12), respectively. The
2-year pEFS and pOS in periods 1 and 2 were 5% versus 15% (p = .53), and 8% ver-
sus 16% (p = .93), respectively.
Conclusion: The implementation of the SIOP PODC guideline did not result in
improved outcomes of Kenyan children with AML. Survival of these children remains
dismal, mainly attributable to early mortality
